These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 33147766)

  • 1. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer.
    Khomiak A; Brunner M; Kordes M; Lindblad S; Miksch RC; Öhlund D; Regel I
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33147766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma.
    Stubbe BE; Madsen PH; Larsen AC; Krarup HB; Pedersen IS; Hansen CP; Johansen JS; Henriksen SD; Thorlacius-Ussing O
    Pancreatology; 2023 Aug; 23(5):512-521. PubMed ID: 37230892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).
    Seufferlein T; Ettrich TJ
    Transl Gastroenterol Hepatol; 2019; 4():21. PubMed ID: 30976724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.
    Giannis D; Moris D; Barbas AS
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind.
    Arsenijevic T; Nicolle R; Bouchart C; D'Haene N; Demetter P; Puleo F; Van Laethem JL
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer.
    Scheufele F; Hartmann D; Friess H
    Transl Gastroenterol Hepatol; 2019; 4():32. PubMed ID: 31231699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future biomarkers for pancreatic adenocarcinoma.
    Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
    Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New challenges in perioperative management of pancreatic cancer.
    Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL
    World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas.
    Mehta S; Bhimani N; Gill AJ; Samra JS; Sahni S; Mittal A
    Front Oncol; 2021; 11():708963. PubMed ID: 34290990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma.
    Agrawal S
    World J Clin Oncol; 2017 Jun; 8(3):255-260. PubMed ID: 28638795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.
    McGowan R; Sally Á; McCabe A; Moran BM; Finn K
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Sulciner ML; Ashley SW; Molina G
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteostasis Dysregulation in Pancreatic Cancer.
    Arpalahti L; Haglund C; Holmberg CI
    Adv Exp Med Biol; 2020; 1233():101-115. PubMed ID: 32274754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.
    Sharma GG; Okada Y; Von Hoff D; Goel A
    Semin Cancer Biol; 2021 Oct; 75():153-168. PubMed ID: 33049362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer.
    Regel I; Mayerle J; Mahajan UM
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
    PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
    Dorman K; Gerckens M; Kruger S; Krueger K; Mayer Z; Rupp A; Zhang D; Weiss L; Westphalen CB; Haas M; Guenther M; Ormanns S; Klawonn F; Werner J; von Bergwelt-Baildon M; Heinemann V; Boeck S; Holdenrieder S
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2463-2474. PubMed ID: 35737090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
    Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
    World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.